Boston Oncology is an innovative biogenerics company redefining excellence in the licensing and local development, manufacturing and distribution of US-quality medicines – across therapeutic areas. Headquartered in Cambridge, Massachusetts, with principal offices and a world-class manufacturing center in Saudi Arabia, Boston Oncology’s work and our team span continents. 

Boston Oncology Arabia is a bio-generic drugs manufacturing company based in the Kingdom of Saudi Arabia. From its headquarters in Riyadh and production facility in Sudair Industrial City, Boston Oncology Arabia provides vital medicines for critical conditions through the local development and manufacturing of internationally licensed, best-in-class therapeutics.

 

 

Investment date June  2024 – Read the Deal Announcement
Website https://bostononcology.com/boston-oncology-arabia/
Sector Pharmaceutical Manufacturing
Region Saudi Arabia
Investment type Growth

 

Investment Rationale

Improve healthcare in underserved communities through best-in-class, affordable, locally developed and manufactured generics and biosimilars. Boston Oncology Arabia is under contract for 3 years as a preferred supplier to King Faisal Specialist Hospital, and has sold to 15 government hospitals. In 2020, it had the first biosimilar product registered with the SFDA for local manufacturing, and has had 44 products in front of the SFDA as of early 2022. The manufacturing center in Saudi Arabia houses a leading-edge GMP certified facility, with an annual vial capacity of over 30 million units, delivering class-leading quality—quickly, reliably, and at affordable prices in the local market. In Saudi Arabia, the company is targeting a portfolio size of +175 products ranging from entry level narcotics to high use injectables, chemotherapies and biologics.

Impact

Access Affordability And Quality 
  • Improve healthcare in underserved communities through 

    best-in-class, affordable, locally developed and manufactured 

    generics and biosimilars.

Future Growth Prospects and Diversity
  • In its Vision 2030 framework, the Kingdom has set bold and ambitious goals for its future. Boston Oncology Arabia is fully aligned with these objectives—improving KSA healthcare services, creating local jobs, employing a predominantly female workforce, in-sourcing innovation, bringing high tech and specialized manufacturing to the region, improving well-being, happiness and opportunity for citizens, producing products for local and regional markets, promoting KSA as a logistical hub for international trade, and contributing to a diverse and sustainable economy.
    ​